Cancer Genes and Genomics Deletion or Epigenetic Silencing of AJAP 1 on 1 p 36 in Glioblastoma
暂无分享,去创建一个
R. McLendon | P. Truszkowski | D. Bigner | S. Gregory | N. Lin | Ningjing Lin | Simon Gregory | ChunhuiDi | KathyBortoff | JinrongFu | Peter Truszkowski | PatrickKillela | ChrisDuncan | Roger McLendon | Darell Bigner | David Cory Adamson | D. C. Adamson
[1] L. Loeb,et al. Mutator phenotype may be required for multistage carcinogenesis. , 1991, Cancer research.
[2] K. Bélanger,et al. Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer. , 1997, Anti-cancer drugs.
[3] F. Lazeyras,et al. Possible efficacy of temozolomide in a patient with gliomatosis cerebri , 2001, Neurology.
[4] M. Westphal,et al. Cost of migration: invasion of malignant gliomas and implications for treatment. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Erwin G. Van Meir,et al. Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. , 2004, The American journal of pathology.
[6] H. Ng,et al. Identification of two contiguous minimally deleted regions on chromosome 1p36.31–p36.32 in oligodendroglial tumours , 2004, British Journal of Cancer.
[7] D. Brat,et al. Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. , 2004, Neuro-oncology.
[8] M. West,et al. Gene expression profiling and genetic markers in glioblastoma survival. , 2005, Cancer research.
[9] R. Kiss,et al. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] T. Parrett,et al. Digital karyotyping technology: exploring the cancer genome , 2005, Expert review of molecular diagnostics.
[11] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[12] S. Gregory,et al. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma , 2005, Oncogene.
[13] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[14] A. Starzinski-Powitz,et al. Targeting of transmembrane protein shrew-1 to adherens junctions is controlled by cytoplasmic sorting motifs. , 2006, Molecular biology of the cell.
[15] Tae-You Kim,et al. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. , 2006, Cancer research.
[16] M. Esteller,et al. Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme , 2007, Journal of Neuro-Oncology.
[17] K. Aldape,et al. The SHREW1 gene, frequently deleted in oligodendrogliomas, functions to inhibit cell adhesion and migration , 2006, Cancer biology & therapy.
[18] D. Louis,et al. Downregulation of RUNX3 and TES by hypermethylation in glioblastoma , 2007, Oncogene.
[19] M. Ruonala,et al. Junction protein shrew-1 influences cell invasion and interacts with invasion-promoting protein CD147. , 2007, Molecular biology of the cell.
[20] Gabriele Schackert,et al. CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. , 2007, Carcinogenesis.
[21] P. Kleihues,et al. Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.
[22] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[23] J. Maris,et al. CHD5, a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas , 2008, Journal of the National Cancer Institute.
[24] P. Lichter,et al. Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma , 2009, Genes, chromosomes & cancer.
[25] J. Uhm. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .
[26] Darell D. Bigner,et al. Glioblastoma Multiforme Oncogenomics and Signaling Pathways , 2009, Clinical medicine. Oncology.
[27] L. Cope,et al. Digital Karyotyping , 2012, Molecular Diagnosis & Therapy.